Research Study on the effect of Eranda moola ( Roots of Ricinus communis) in the treatment of raised lipids level

A Randomized Controlled Trial to evaluate the effect of Eranda Moola (Root of Ricinus communis) in the management of Dyslipidemia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/02/017743

Enrollment

140

Registered

2019-02-20

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: Root of Ricinus communis: 80 mg per kg body weight in morning on empty stomach with Honey for 8 weeks Control Intervention1: Atorvastatin: 20 mg OD for 8 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with Direct LDL-C more than 130 at the time of screening Subjects willing to follow the procedures as per the study protocol and voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1)Subjects not willing for trial 2)Subjects with Diabetes Mellitus Type I and Type 2 Diabetes Mellitus 3)Subjects with uncontrolled Hy pothyroidism or Hyperthyroidism 4)Known cases of Severe/Chronic hepatic or renal disease 5)Known subject of any active malignancy 6)Subjects giving history of significant cardiovascular event less than 12 weeks prior to randomization 7)Subjects with uncontrolled or Malignant Hypertension 8)Subjects ECG demonstrating any signs of uncontrolled arrhythmia or acute ischemia 9)Subjects X- ray chest showing any active lesion of tuberculosis 10)Subjects having known HIV infection 11)Subjects using any other investigational drug within 1 month prior to recruitment 12)Pregnant and Lactating females 13)Subjects currently participating in any other Clinical study 14)Any other medical or surgical condition considered unsuitable for patient participation in the study as per InvestigatorÃ¢â?¬•s judgment

Design outcomes

Primary

Measure	Time frame
1) Effect on the change in direct LDL-C level at the end of study (08 weeks) 2)Effect on the change in Triglycerides levels at the end of study (08 weeks) Timepoint: at the end of 8 weeks	—

Secondary

Measure	Time frame
1.Change in Total Cholesterol Triglycerides LDL and HDL at the end of 4 and 8 weeks 2.Change in Body Weight BMI Waist circumference and Waist to hip ratio at the end of 4 & 8 weeks 3.Overall efficacy of the study and control product as per the physician at the end of 8 weeks 4.Safety assessment by assessing adverse drug reactions abnormal laboratories values at the end of 4 and 8 weeks 5.Overall safety assessment of the intervention as per the physician at the end of 8weeks Timepoint: at the end of 4 and 8 weeks	—

Measure

Time frame

1.Change in Total Cholesterol Triglycerides LDL and HDL at the end of 4 and 8 weeks 2.Change in Body Weight BMI Waist circumference and Waist to hip ratio at the end of 4 & 8 weeks 3.Overall efficacy of the study and control product as per the physician at the end of 8 weeks 4.Safety assessment by assessing adverse drug reactions abnormal laboratories values at the end of 4 and 8 weeks 5.Overall safety assessment of the intervention as per the physician at the end of 8weeks Timepoint: at the end of 4 and 8 weeks

—

Countries

India

Contacts

Public ContactDr Sunil S Borkar

Shri Gurudeo Ayurved College Gurukunj Ashram

sborkar25@gmail.com9822361760

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026